Drug Profile
APN 421
Alternative Names: APN421Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Apeiron Biologics
- Class Antineoplastics; Small molecules
- Mechanism of Action Checkpoint kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Solid-tumours in Austria
- 05 Mar 2018 Preclinical trials in Solid tumours in Austria (unspecified route) (Apeiron Biologics pipeline, March 2018)